{{Short description|Monoclonal antibody}} {{cs1 config|name-list-style=vanc|display-authors=6}} {{Drugbox | type = mab | image = | alt = | mab_type = mab | source = zu | target = LOXL2 | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 1318075-13-6 | ATC_prefix = none | ATC_suffix = | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 11Z5AIU653 | PubChem = | IUPHAR_ligand = 8412 | DrugBank = | ChemSpiderID = none | C=6558 | H=10134 | N=1736 | O=2037 | S=50 }}

'''Simtuzumab''' (INN; formerly '''GS 6624''') is a humanized monoclonal antibody designed for the treatment of fibrosis.<ref>[http://www.ama-assn.org/resources/doc/usan/simtuzumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Simtuzumab], ''American Medical Association''.</ref> It binds to LOXL2 and acts as an immunomodulator.<ref>{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 | journal = WHO Drug Information | volume = 26 | issue = 2 | year = 2012 | url = https://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf }}</ref> In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy.<ref>{{cite web | title = Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis | date = 5 January 2016 | publisher = Gilead | url = http://www.gilead.com/news/press-releases/2016/1/gilead-terminates-phase-2-study-of-simtuzumab-in-patients-with-idiopathic-pulmonary-fibrosis }} </ref><ref name="Chen_2020">{{cite journal | vauthors = Chen W, Yang A, Jia J, Popov YV, Schuppan D, You H | title = Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis | journal = Hepatology | volume = 72 | issue = 2 | pages = 729–741 | date = August 2020 | pmid = 32176358 | doi = 10.1002/hep.31236 }}</ref>

== References == {{reflist}}

Category:Monoclonal antibodies

{{monoclonal-antibody-stub}} {{monoclonals for tumors}}